Determinants of plasma fibrin clot lysis measured using three different assays in healthy subjects.


Journal

Thrombosis research
ISSN: 1879-2472
Titre abrégé: Thromb Res
Pays: United States
ID NLM: 0326377

Informations de publication

Date de publication:
01 2021
Historique:
received: 05 04 2020
revised: 26 08 2020
accepted: 10 10 2020
pubmed: 7 11 2020
medline: 22 6 2021
entrez: 6 11 2020
Statut: ppublish

Résumé

Several methods for measuring fibrinolytic capacity in plasma have been developed yielding frequently inconsistent results. We investigated which factors determine fibrinolytic capacity in three plasma-based assays. In 80 apparently healthy controls (aged 43 ± 10 years, 50 women [62.5%]) we evaluated fibrinolysis using three assays: (1) by Pieters et al. (CLT2018), (2) by Lisman et al. (CLT), and (3) by Carter et al. (Lys50). Coagulation factors and fibrinolytic proteins, including histidine-rich glycoprotein (HRG) and γ'-fibrinogen, were determined. Regression models were performed to identify determinants of lysis times. Positive correlations were observed between CLT2018 and both CLT (r = 0.73) and Lys50 (r = 0.61), as well as between CLT and Lys50 (r = 0.46, all p < 0.001). The main determinants of both CLT2018 and CLT were plasminogen activator inhibitor-1 (PAI-1), followed by thrombin-activatable fibrinolysis inhibitor (TAFI) and α We showed that apart from PAI-1, TAFI, and α

Identifiants

pubmed: 33157491
pii: S0049-3848(20)30558-2
doi: 10.1016/j.thromres.2020.10.014
pii:
doi:

Substances chimiques

Fibrin 9001-31-4
Carboxypeptidase B2 EC 3.4.17.20

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1-7

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Auteurs

Jakub Siudut (J)

Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Center for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland.

Teresa Iwaniec (T)

Department of Medicine, Jagiellonian University Medical College, Krakow, Poland.

Krzysztof Plens (K)

KCRI, Krakow, Poland.

Marlien Pieters (M)

Centre of Excellence for Nutrition, North-West University, Potchefstroom, South Africa.

Anetta Undas (A)

Institute of Cardiology, Jagiellonian University Medical College, Krakow, Poland; Krakow Center for Medical Research and Technologies, John Paul II Hospital, Krakow, Poland. Electronic address: mmundas@cyf-kr.edu.pl.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH